Skip to main
  1. Stocks
  2. Arcutis Biotherapeutics
  3. Forecast
ARQT

Arcutis Biotherapeutics (ARQT) Stock Forecast & Price Target

Arcutis Biotherapeutics (ARQT) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Arcutis Biotherapeutics is attractive fundamentally because ZORYVE has become a differentiated branded topical franchise across plaque psoriasis, atopic dermatitis, and seborrheic dermatitis, with foam and cream formulations matching distinct patient-use cases and a potent PDE4 mechanism that supports best-in-class efficacy and tolerability. Commercial execution is strong, as reported Zoryve sales rose from $29M in 2023 to $167M in 2024 and $372M in 2025, while 2Q26 Zoryve sales reached $129.9M, up 59% year over year, contributing to raised 2026 net product sales guidance of $525M to $540M and positive net income of $15.0M in 2Q26. The outlook is further strengthened by limited direct branded competition in seborrheic dermatitis, expanding access and sales infrastructure, and multiple upside catalysts from vitiligo, hidradenitis suppurativa, and ARQ-234 that are not yet reflected in the model.

Bears say

Arcutis Biotherapeutics is viewed negatively because its growth case hinges on multiple approvals and a timely 2/23/27 PDUFA that are not guaranteed, while Zoryve still needs approval in scalp psoriasis. The company also faces intense commercialization risk from generic topical products and Vtama, with uptake dependent on physician demand, payor access, and prior authorization, while higher gross-to-net discounts could pressure the 2026E Zoryve guide of $525–$540M. On top of that, reliance on Interquim for supply, rising operating expenses, and the need for additional capital create meaningful execution and financing risk.

Arcutis Biotherapeutics (ARQT) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arcutis Biotherapeutics and is not a guaranteed prediction by Public.com or investment advice.

Arcutis Biotherapeutics (ARQT) Analyst Forecast & Price Prediction

Get the latest Arcutis Biotherapeutics (ARQT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Arcutis Biotherapeutics (ARQT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arcutis Biotherapeutics (ARQT) Forecast

Analysts have given Arcutis Biotherapeutics (ARQT) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Arcutis Biotherapeutics (ARQT) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arcutis Biotherapeutics (ARQT)


Arcutis Biotherapeutics (ARQT) Analyst Forecast & Price Prediction

Get the latest Arcutis Biotherapeutics (ARQT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Arcutis Biotherapeutics (ARQT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ARQT stock data and trends